Niclosamide reduces COVID-19 risk: real-time meta analysis of 7 studies
, Dec 2025
55th treatment shown to reduce risk in
August 2025, now with p = 0.0069 from 7 studies.
Lower risk for recovery.
No treatment is 100% effective. Protocols
combine treatments.
6,300+ studies for
210+ treatments. c19early.org
|
Significantly lower risk is seen for recovery. 3 studies from 3 independent teams in 3 countries show significant benefit.
Meta analysis using the most serious outcome reported shows 28% [9‑43%] lower risk. Results are similar for higher quality and peer-reviewed studies. Currently all studies are RCTs.
Control Niclosamide
Currently there is limited data, with only 20 control events for the most serious outcome in trials to date.
1 RCT with 200 patients has not reported results (4 years late)1.
No treatment is 100% effective. Protocols combine safe and effective options with individual risk/benefit analysis and monitoring. Other treatments are more effective. All data and sources to reproduce this analysis are in the appendix.
Covid Analysis et al., Dec 2025, preprint, 1 author.